|
HY-100004-100mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-1 [CAS 1644060-37-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100004-2mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-1 [CAS 1644060-37-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100004-5mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-1 [CAS 1644060-37-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100004-50mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-1 [CAS 1644060-37-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100005A-1mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-2 (sodium salt) [CAS 2070009-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-100005A-10mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-2 (sodium salt) [CAS 2070009-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-100005A-25mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-2 (sodium salt) [CAS 2070009-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-100005A-5mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-2 (sodium salt) [CAS 2070009-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-100005A-50mg
|
MedChemexpress LLC
|
Fumarate hydratase-IN-2 (sodium salt) [CAS 2070009-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-100012-10mg
|
MedChemexpress LLC
|
CBR-5884 [CAS 681159-27-3]
|
|
Cancer-programmed cell death
|
|
|
HY-100012-100mg
|
MedChemexpress LLC
|
CBR-5884 [CAS 681159-27-3]
|
|
Cancer-programmed cell death
|
|
|
HY-100012-25mg
|
MedChemexpress LLC
|
CBR-5884 [CAS 681159-27-3]
|
|
Cancer-programmed cell death
|
|
|
HY-100012-5mg
|
MedChemexpress LLC
|
CBR-5884 [CAS 681159-27-3]
|
|
Cancer-programmed cell death
|
|
|
HY-100012-50mg
|
MedChemexpress LLC
|
CBR-5884 [CAS 681159-27-3]
|
|
Cancer-programmed cell death
|
|
|
HY-100013A1-10mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100013A1-25mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100013A1-5mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100013A1-50mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100014-1mg
|
MedChemexpress LLC
|
KDM5A-IN-1 [CAS 1905481-36-8]
|
|
Cancer-programmed cell death
|
|
|
HY-100014-10mg
|
MedChemexpress LLC
|
KDM5A-IN-1 [CAS 1905481-36-8]
|
|
Cancer-programmed cell death
|
|
|
HY-100014-100mg
|
MedChemexpress LLC
|
KDM5A-IN-1 [CAS 1905481-36-8]
|
|
Cancer-programmed cell death
|
|
|
HY-100014-5mg
|
MedChemexpress LLC
|
KDM5A-IN-1 [CAS 1905481-36-8]
|
|
Cancer-programmed cell death
|
|
|
HY-100014-50mg
|
MedChemexpress LLC
|
KDM5A-IN-1 [CAS 1905481-36-8]
|
|
Cancer-programmed cell death
|
|
|
HY-100015-10mg
|
MedChemexpress LLC
|
Mivebresib [CAS 1445993-26-9]
|
|
Cancer-programmed cell death
|
|
|
HY-100015-100mg
|
MedChemexpress LLC
|
Mivebresib [CAS 1445993-26-9]
|
|
Cancer-programmed cell death
|
|
